Germany A roundup of some of the most important recent news from German pharma, including state honours for the founders of BioNTech, the latest on vaccines and lockdowns in the country, as well as the German pharma firms making international investments and predicting mid-term growth. Pharma companies must deliver promised…
Global From almost being de-listed by the NASDAQ stock index in 2018 due to poor financial performance, US vaccine firm Novavax has completed a remarkable turnaround. Now the holder of one of the world’s leading COVID-19 vaccine candidates and the recipient of billions of dollars in funding from the US government…
Global The global rush to secure access to COVID-19 vaccines has led to accusations that richer countries are hoarding supply at the expense of poorer nations. While some are calling for a relaxation of intellectual property (IP) to allow less-developed nations to vaccinate their populations, Big Pharma is resistant, arguing that…
Singapore Nawal Roy of global digital health platform Holmusk which aims to establish data as a core utility to the treatment of behavioural health disorders explains the challenges of working in behavioural health, why continuing inflows of talent and capital to the space are so important, and the benefits of basing…
Italy The latest from Italian pharma, including the foreign minister’s plea for delivering on COVID-19 vaccine contracts, glass vial manufacturer Stevenato’s USD five billion valuation, AIFA’s approval of Novartis’s Zolgensma, and how Italy has become the first EU country to manufacture Russia’s Sputnik V vaccine. COVID-19 vaccine vial maker Stevanato…
USA Dan Leonard, president and CEO of the Association for Accessible Medicines (AAM) since August 2020, outlines his key agenda priorities as head of the USA’s largest generic industry body, how the COVID-19 pandemic has altered the discussion around generics and essential medicines, and his hopes for the Biden administration …
USA PhRMA’s Stephen J. Ubl outlines two ways in which the new US presidency can help lower healthcare costs and why biopharmaceutical companies support changes to the system that can lower US patients’ out-of-pocket spending and continue to drive innovation. By bringing an end to the pandemic and lowering out-of-pocket…
China The latest from Chinese pharma, including a new deal between AstraZeneca and Junshi Biosciences; Innoforce and dMed’s R&D collab; and investment news on Clover Biopharmaceuticals, Sciwind Biosciences, and Gensciences. AstraZeneca signs deal with Chinese biotech Junshi Biosciences to market anti-PD-1 cancer drug in China https://www.biopharma-reporter.com/Article/2021/03/01/AstraZeneca-betting-on-China-s-PD-1-cancer-market AstraZeneca has signed a…
Mexico The latest from Mexico’s fight against COVID-19, including news of vaccine tourism into the US, how China’s CanSino is filling the gaps left by Western companies, and AMLO’s call for UN intervention on vaccine rollout. The Mexican Elites Who Are Traveling to the U.S. to Get Vaccinated (Slate) https://slate.com/technology/2021/02/covid-19-vaccine-tourism-mexico-elites.html…
USA With Rare Disease Day coming up on February 28th, one of the leading organizations dedicated to serving affected patients in the US, the National Organization for Rare Disorders (NORD), is making a push to put the spotlight on the limited access to diagnosis, treatment and care suffered by rare disease…
USA The AAM’s Dan Leonard highlights the savings impact that generic and biosimilar medicines have on US healthcare today and introduces the ‘Secure Our Meds’ campaign which aims to educate policymakers on the importance of generic and biosimilar market competition and how it can be safeguarded. More than 35 years…
Global Thomas Cueni of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) highlights the incredible progress of COVID-19 vaccines from bench to market in less than a year and introduces the IFPMA’s new #TeamVaccines campaign, shedding light on the personal stories behind this miraculous effort. The story of COVID-19…
See our Cookie Privacy Policy Here